Poolbeg Pharma licences first-in-class broad spectrum RNA-based immunotherapy
Poolbeg Pharma licences first-in-class broad spectrum RNA-based immunotherapy
Source: directorstalkinterviews.com
Stay updated with breaking news from Nigel Dimmock. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Poolbeg Pharma licences first-in-class broad spectrum RNA-based immunotherapy
Immunotherapy could be used to treat conditions such as influenza and Covid-19
Poolbeg Pharma PLC (AIM:POLB) (Poolbeg Pharma PLC (AIM:POLB)) Jeremy Skillington joins Proactive London to talk about their deal for an...
If we have learnt anything from the last two years, it’s that virus protection is not to be sniffed at - News - PharmaTimes
Proactive Research analyst Robin Davison presents his report on Poolbeg Pharma PLC (AIM:POLB) (Poolbeg Pharma PLC (AIM:POLB)) after the...